pharmaobservatory 0.1.13 → 0.1.15
This diff represents the content of publicly available package versions that have been released to one of the supported registries. The information contained in this diff is provided for informational purposes only and reflects changes between package versions as they appear in their respective public registries.
- checksums.yaml +4 -4
- data/README.md +25 -5
- data/docs/BiomarkerValidationRow.md +1 -1
- data/docs/ChangesList200Response.md +26 -0
- data/docs/ChangesList200ResponseBuildState.md +20 -0
- data/docs/ChangesList200ResponseItemsInner.md +48 -0
- data/docs/ChangesList200ResponseItemsInnerEntryKeys.md +18 -0
- data/docs/CompaniesApi.md +86 -4
- data/docs/CompanyAssetCollisionsResponse.md +58 -0
- data/docs/CompanyAssetCollisionsRow.md +68 -0
- data/docs/CompanyCompetitorsRow.md +16 -32
- data/docs/CompanyFinancialsRow.md +18 -0
- data/docs/ConditionAdverseEventsRow.md +5 -1
- data/docs/SubscriptionsApi.md +282 -0
- data/docs/SubscriptionsCreate201Response.md +22 -0
- data/docs/SubscriptionsCreate201ResponseSubscription.md +28 -0
- data/docs/SubscriptionsCreate201ResponseSubscriptionTarget.md +22 -0
- data/docs/SubscriptionsCreateRequest.md +20 -0
- data/docs/SubscriptionsDelete200Response.md +24 -0
- data/docs/SubscriptionsList200Response.md +22 -0
- data/docs/SubscriptionsList200ResponseSubscriptionsInner.md +28 -0
- data/docs/SubscriptionsList200ResponseSubscriptionsInnerTarget.md +26 -0
- data/docs/SubscriptionsList200ResponseSubscriptionsInnerTargetFilters.md +18 -0
- data/lib/pharmaobservatory/api/companies_api.rb +93 -2
- data/lib/pharmaobservatory/api/subscriptions_api.rb +261 -0
- data/lib/pharmaobservatory/models/biomarker_validation_row.rb +1 -1
- data/lib/pharmaobservatory/models/changes_list200_response.rb +343 -0
- data/lib/pharmaobservatory/models/changes_list200_response_build_state.rb +263 -0
- data/lib/pharmaobservatory/models/changes_list200_response_items_inner.rb +627 -0
- data/lib/pharmaobservatory/models/changes_list200_response_items_inner_entry_keys.rb +237 -0
- data/lib/pharmaobservatory/models/company_asset_collisions_response.rb +478 -0
- data/lib/pharmaobservatory/models/company_asset_collisions_row.rb +502 -0
- data/lib/pharmaobservatory/models/company_competitors_row.rb +61 -153
- data/lib/pharmaobservatory/models/company_financials_row.rb +100 -1
- data/lib/pharmaobservatory/models/condition_adverse_events_row.rb +27 -5
- data/lib/pharmaobservatory/models/subscriptions_create201_response.rb +289 -0
- data/lib/pharmaobservatory/models/subscriptions_create201_response_subscription.rb +369 -0
- data/lib/pharmaobservatory/models/subscriptions_create201_response_subscription_target.rb +289 -0
- data/lib/pharmaobservatory/models/subscriptions_create_request.rb +263 -0
- data/lib/pharmaobservatory/models/subscriptions_delete200_response.rb +315 -0
- data/lib/pharmaobservatory/models/subscriptions_list200_response.rb +291 -0
- data/lib/pharmaobservatory/models/subscriptions_list200_response_subscriptions_inner.rb +369 -0
- data/lib/pharmaobservatory/models/subscriptions_list200_response_subscriptions_inner_target.rb +277 -0
- data/lib/pharmaobservatory/models/subscriptions_list200_response_subscriptions_inner_target_filters.rb +237 -0
- data/lib/pharmaobservatory/version.rb +1 -1
- data/lib/pharmaobservatory.rb +16 -0
- metadata +34 -2
|
@@ -14,7 +14,7 @@ require 'date'
|
|
|
14
14
|
require 'time'
|
|
15
15
|
|
|
16
16
|
module PharmaObservatory
|
|
17
|
-
# One row of the company_competitors dataset: one row per ordered company pair: a company and one of the top 25 companies of each competitor_class by
|
|
17
|
+
# One row of the company_competitors dataset: one row per ordered company pair: a company and one of the top 25 companies of each competitor_class by asset collision. A grouped request returns the group columns and the measures instead, as additional properties.
|
|
18
18
|
class CompanyCompetitorsRow
|
|
19
19
|
# Company level: the company the row is about; the entry key for the companies object type.
|
|
20
20
|
attr_accessor :company_id
|
|
@@ -43,59 +43,35 @@ module PharmaObservatory
|
|
|
43
43
|
# The competitor's class: industry, or non_industry (not classed as industry by the sponsor-class rule: academic, hospital, government, nonprofit, and any record the rule does not reach). competitor_rank restarts at 1 within each class, so filter or sort on this column first.
|
|
44
44
|
attr_accessor :competitor_class
|
|
45
45
|
|
|
46
|
-
# How many companies of this competitor_class
|
|
46
|
+
# How many companies of this competitor_class had at least one asset collision with the company before the top 25 were kept. The same value on every row of one company and class.
|
|
47
47
|
attr_accessor :n_class_candidates
|
|
48
48
|
|
|
49
49
|
# The competitor's rank within its competitor_class for the company by competitor_score (1 is the highest).
|
|
50
50
|
attr_accessor :competitor_rank
|
|
51
51
|
|
|
52
|
-
#
|
|
52
|
+
# The weighted share of the company's live target families that the competitor's live assets collide with, 0 to 100, rounded to four places. Each colliding family counts its best collision weight (rarity of the family across companies, times factors for same action, a shared indication, the least advanced stage, recency and a head-to-head trial), capped at the family's rarity weight; the sum is divided by the rarity weights of ALL the company's families.
|
|
53
53
|
attr_accessor :competitor_score
|
|
54
54
|
|
|
55
|
-
#
|
|
56
|
-
attr_accessor :
|
|
55
|
+
# Asset pairs (a drug of the company, a drug of the competitor) that act on a common target.
|
|
56
|
+
attr_accessor :n_collisions
|
|
57
57
|
|
|
58
|
-
#
|
|
59
|
-
attr_accessor :
|
|
58
|
+
# Target families of the company's live assets that the competitor collides with.
|
|
59
|
+
attr_accessor :n_colliding_families
|
|
60
60
|
|
|
61
|
-
#
|
|
62
|
-
attr_accessor :
|
|
61
|
+
# Target families of the company's own live, owned assets; the denominator of competitor_score is their rarity weights.
|
|
62
|
+
attr_accessor :n_subject_families
|
|
63
63
|
|
|
64
|
-
#
|
|
65
|
-
attr_accessor :
|
|
64
|
+
# Asset pairs whose drugs act on the shared target with the same action type.
|
|
65
|
+
attr_accessor :n_same_action
|
|
66
66
|
|
|
67
|
-
#
|
|
68
|
-
attr_accessor :
|
|
67
|
+
# Asset pairs whose programs share at least one disease area.
|
|
68
|
+
attr_accessor :n_shared_indication_pairs
|
|
69
69
|
|
|
70
|
-
#
|
|
71
|
-
attr_accessor :
|
|
70
|
+
# Distinct trials led by either company in which one drug of a pair is experimental and the other an active comparator.
|
|
71
|
+
attr_accessor :n_head_to_head_trials
|
|
72
72
|
|
|
73
|
-
#
|
|
74
|
-
attr_accessor :
|
|
75
|
-
|
|
76
|
-
# Shared targets that both companies have taken to phase 2 or later.
|
|
77
|
-
attr_accessor :n_phase_overlap_targets
|
|
78
|
-
|
|
79
|
-
# Targets the company pursues (the Jaccard denominator).
|
|
80
|
-
attr_accessor :n_company_targets
|
|
81
|
-
|
|
82
|
-
# Targets the competitor pursues.
|
|
83
|
-
attr_accessor :n_competitor_targets
|
|
84
|
-
|
|
85
|
-
# Disease areas in the company's top 25.
|
|
86
|
-
attr_accessor :n_company_indications
|
|
87
|
-
|
|
88
|
-
# Disease areas in the competitor's top 25.
|
|
89
|
-
attr_accessor :n_competitor_indications
|
|
90
|
-
|
|
91
|
-
# Up to 5 shared target gene symbols, by combined phase then combined trials. An empty list when none.
|
|
92
|
-
attr_accessor :top_shared_targets
|
|
93
|
-
|
|
94
|
-
# Up to 5 shared disease area names, by combined trial count. An empty list when none.
|
|
95
|
-
attr_accessor :top_shared_indications
|
|
96
|
-
|
|
97
|
-
# Up to 3 shared mechanisms written as a gene symbol and an action, by combined phase then combined trials. An empty list when none.
|
|
98
|
-
attr_accessor :top_shared_mechanisms
|
|
73
|
+
# Up to 3 strongest asset pairs as text: \"drug A / drug B: target family, stage, N shared indications\". The stage is the less advanced of the two programs. An ownership_basis of inferred_lead on the underlying pair (see company_asset_collisions) is an inference.
|
|
74
|
+
attr_accessor :top_collisions
|
|
99
75
|
|
|
100
76
|
# Distinct trials on which the company and the competitor are both named as sponsors, counted over their subtrees; 0 when none. A consortium trial (more than 25 sponsor companies) is left out.
|
|
101
77
|
attr_accessor :n_cosponsored_trials
|
|
@@ -115,21 +91,13 @@ module PharmaObservatory
|
|
|
115
91
|
:'n_class_candidates' => :'n_class_candidates',
|
|
116
92
|
:'competitor_rank' => :'competitor_rank',
|
|
117
93
|
:'competitor_score' => :'competitor_score',
|
|
118
|
-
:'
|
|
119
|
-
:'
|
|
120
|
-
:'
|
|
121
|
-
:'
|
|
122
|
-
:'
|
|
123
|
-
:'
|
|
124
|
-
:'
|
|
125
|
-
:'n_phase_overlap_targets' => :'n_phase_overlap_targets',
|
|
126
|
-
:'n_company_targets' => :'n_company_targets',
|
|
127
|
-
:'n_competitor_targets' => :'n_competitor_targets',
|
|
128
|
-
:'n_company_indications' => :'n_company_indications',
|
|
129
|
-
:'n_competitor_indications' => :'n_competitor_indications',
|
|
130
|
-
:'top_shared_targets' => :'top_shared_targets',
|
|
131
|
-
:'top_shared_indications' => :'top_shared_indications',
|
|
132
|
-
:'top_shared_mechanisms' => :'top_shared_mechanisms',
|
|
94
|
+
:'n_collisions' => :'n_collisions',
|
|
95
|
+
:'n_colliding_families' => :'n_colliding_families',
|
|
96
|
+
:'n_subject_families' => :'n_subject_families',
|
|
97
|
+
:'n_same_action' => :'n_same_action',
|
|
98
|
+
:'n_shared_indication_pairs' => :'n_shared_indication_pairs',
|
|
99
|
+
:'n_head_to_head_trials' => :'n_head_to_head_trials',
|
|
100
|
+
:'top_collisions' => :'top_collisions',
|
|
133
101
|
:'n_cosponsored_trials' => :'n_cosponsored_trials'
|
|
134
102
|
}
|
|
135
103
|
end
|
|
@@ -159,21 +127,13 @@ module PharmaObservatory
|
|
|
159
127
|
:'n_class_candidates' => :'Integer',
|
|
160
128
|
:'competitor_rank' => :'Integer',
|
|
161
129
|
:'competitor_score' => :'Float',
|
|
162
|
-
:'
|
|
163
|
-
:'
|
|
164
|
-
:'
|
|
165
|
-
:'
|
|
166
|
-
:'
|
|
167
|
-
:'
|
|
168
|
-
:'
|
|
169
|
-
:'n_phase_overlap_targets' => :'Integer',
|
|
170
|
-
:'n_company_targets' => :'Integer',
|
|
171
|
-
:'n_competitor_targets' => :'Integer',
|
|
172
|
-
:'n_company_indications' => :'Integer',
|
|
173
|
-
:'n_competitor_indications' => :'Integer',
|
|
174
|
-
:'top_shared_targets' => :'Array<String>',
|
|
175
|
-
:'top_shared_indications' => :'Array<String>',
|
|
176
|
-
:'top_shared_mechanisms' => :'Array<String>',
|
|
130
|
+
:'n_collisions' => :'Integer',
|
|
131
|
+
:'n_colliding_families' => :'Integer',
|
|
132
|
+
:'n_subject_families' => :'Integer',
|
|
133
|
+
:'n_same_action' => :'Integer',
|
|
134
|
+
:'n_shared_indication_pairs' => :'Integer',
|
|
135
|
+
:'n_head_to_head_trials' => :'Integer',
|
|
136
|
+
:'top_collisions' => :'Array<String>',
|
|
177
137
|
:'n_cosponsored_trials' => :'Integer'
|
|
178
138
|
}
|
|
179
139
|
end
|
|
@@ -193,21 +153,13 @@ module PharmaObservatory
|
|
|
193
153
|
:'n_class_candidates',
|
|
194
154
|
:'competitor_rank',
|
|
195
155
|
:'competitor_score',
|
|
196
|
-
:'
|
|
197
|
-
:'
|
|
198
|
-
:'
|
|
199
|
-
:'
|
|
200
|
-
:'
|
|
201
|
-
:'
|
|
202
|
-
:'
|
|
203
|
-
:'n_phase_overlap_targets',
|
|
204
|
-
:'n_company_targets',
|
|
205
|
-
:'n_competitor_targets',
|
|
206
|
-
:'n_company_indications',
|
|
207
|
-
:'n_competitor_indications',
|
|
208
|
-
:'top_shared_targets',
|
|
209
|
-
:'top_shared_indications',
|
|
210
|
-
:'top_shared_mechanisms',
|
|
156
|
+
:'n_collisions',
|
|
157
|
+
:'n_colliding_families',
|
|
158
|
+
:'n_subject_families',
|
|
159
|
+
:'n_same_action',
|
|
160
|
+
:'n_shared_indication_pairs',
|
|
161
|
+
:'n_head_to_head_trials',
|
|
162
|
+
:'top_collisions',
|
|
211
163
|
:'n_cosponsored_trials'
|
|
212
164
|
])
|
|
213
165
|
end
|
|
@@ -276,69 +228,33 @@ module PharmaObservatory
|
|
|
276
228
|
self.competitor_score = attributes[:'competitor_score']
|
|
277
229
|
end
|
|
278
230
|
|
|
279
|
-
if attributes.key?(:'
|
|
280
|
-
self.
|
|
281
|
-
end
|
|
282
|
-
|
|
283
|
-
if attributes.key?(:'mechanism_sim')
|
|
284
|
-
self.mechanism_sim = attributes[:'mechanism_sim']
|
|
285
|
-
end
|
|
286
|
-
|
|
287
|
-
if attributes.key?(:'indication_sim')
|
|
288
|
-
self.indication_sim = attributes[:'indication_sim']
|
|
289
|
-
end
|
|
290
|
-
|
|
291
|
-
if attributes.key?(:'phase_sim')
|
|
292
|
-
self.phase_sim = attributes[:'phase_sim']
|
|
293
|
-
end
|
|
294
|
-
|
|
295
|
-
if attributes.key?(:'n_shared_targets')
|
|
296
|
-
self.n_shared_targets = attributes[:'n_shared_targets']
|
|
297
|
-
end
|
|
298
|
-
|
|
299
|
-
if attributes.key?(:'n_shared_mechanisms')
|
|
300
|
-
self.n_shared_mechanisms = attributes[:'n_shared_mechanisms']
|
|
301
|
-
end
|
|
302
|
-
|
|
303
|
-
if attributes.key?(:'n_shared_indications')
|
|
304
|
-
self.n_shared_indications = attributes[:'n_shared_indications']
|
|
231
|
+
if attributes.key?(:'n_collisions')
|
|
232
|
+
self.n_collisions = attributes[:'n_collisions']
|
|
305
233
|
end
|
|
306
234
|
|
|
307
|
-
if attributes.key?(:'
|
|
308
|
-
self.
|
|
235
|
+
if attributes.key?(:'n_colliding_families')
|
|
236
|
+
self.n_colliding_families = attributes[:'n_colliding_families']
|
|
309
237
|
end
|
|
310
238
|
|
|
311
|
-
if attributes.key?(:'
|
|
312
|
-
self.
|
|
239
|
+
if attributes.key?(:'n_subject_families')
|
|
240
|
+
self.n_subject_families = attributes[:'n_subject_families']
|
|
313
241
|
end
|
|
314
242
|
|
|
315
|
-
if attributes.key?(:'
|
|
316
|
-
self.
|
|
243
|
+
if attributes.key?(:'n_same_action')
|
|
244
|
+
self.n_same_action = attributes[:'n_same_action']
|
|
317
245
|
end
|
|
318
246
|
|
|
319
|
-
if attributes.key?(:'
|
|
320
|
-
self.
|
|
247
|
+
if attributes.key?(:'n_shared_indication_pairs')
|
|
248
|
+
self.n_shared_indication_pairs = attributes[:'n_shared_indication_pairs']
|
|
321
249
|
end
|
|
322
250
|
|
|
323
|
-
if attributes.key?(:'
|
|
324
|
-
self.
|
|
325
|
-
end
|
|
326
|
-
|
|
327
|
-
if attributes.key?(:'top_shared_targets')
|
|
328
|
-
if (value = attributes[:'top_shared_targets']).is_a?(Array)
|
|
329
|
-
self.top_shared_targets = value
|
|
330
|
-
end
|
|
331
|
-
end
|
|
332
|
-
|
|
333
|
-
if attributes.key?(:'top_shared_indications')
|
|
334
|
-
if (value = attributes[:'top_shared_indications']).is_a?(Array)
|
|
335
|
-
self.top_shared_indications = value
|
|
336
|
-
end
|
|
251
|
+
if attributes.key?(:'n_head_to_head_trials')
|
|
252
|
+
self.n_head_to_head_trials = attributes[:'n_head_to_head_trials']
|
|
337
253
|
end
|
|
338
254
|
|
|
339
|
-
if attributes.key?(:'
|
|
340
|
-
if (value = attributes[:'
|
|
341
|
-
self.
|
|
255
|
+
if attributes.key?(:'top_collisions')
|
|
256
|
+
if (value = attributes[:'top_collisions']).is_a?(Array)
|
|
257
|
+
self.top_collisions = value
|
|
342
258
|
end
|
|
343
259
|
end
|
|
344
260
|
|
|
@@ -379,21 +295,13 @@ module PharmaObservatory
|
|
|
379
295
|
n_class_candidates == o.n_class_candidates &&
|
|
380
296
|
competitor_rank == o.competitor_rank &&
|
|
381
297
|
competitor_score == o.competitor_score &&
|
|
382
|
-
|
|
383
|
-
|
|
384
|
-
|
|
385
|
-
|
|
386
|
-
|
|
387
|
-
|
|
388
|
-
|
|
389
|
-
n_phase_overlap_targets == o.n_phase_overlap_targets &&
|
|
390
|
-
n_company_targets == o.n_company_targets &&
|
|
391
|
-
n_competitor_targets == o.n_competitor_targets &&
|
|
392
|
-
n_company_indications == o.n_company_indications &&
|
|
393
|
-
n_competitor_indications == o.n_competitor_indications &&
|
|
394
|
-
top_shared_targets == o.top_shared_targets &&
|
|
395
|
-
top_shared_indications == o.top_shared_indications &&
|
|
396
|
-
top_shared_mechanisms == o.top_shared_mechanisms &&
|
|
298
|
+
n_collisions == o.n_collisions &&
|
|
299
|
+
n_colliding_families == o.n_colliding_families &&
|
|
300
|
+
n_subject_families == o.n_subject_families &&
|
|
301
|
+
n_same_action == o.n_same_action &&
|
|
302
|
+
n_shared_indication_pairs == o.n_shared_indication_pairs &&
|
|
303
|
+
n_head_to_head_trials == o.n_head_to_head_trials &&
|
|
304
|
+
top_collisions == o.top_collisions &&
|
|
397
305
|
n_cosponsored_trials == o.n_cosponsored_trials
|
|
398
306
|
end
|
|
399
307
|
|
|
@@ -406,7 +314,7 @@ module PharmaObservatory
|
|
|
406
314
|
# Calculates hash code according to all attributes.
|
|
407
315
|
# @return [Integer] Hash code
|
|
408
316
|
def hash
|
|
409
|
-
[company_id, company_name, group_id, group_name, competitor_company_id, competitor_company_name, competitor_group_id, competitor_group_name, competitor_class, n_class_candidates, competitor_rank, competitor_score,
|
|
317
|
+
[company_id, company_name, group_id, group_name, competitor_company_id, competitor_company_name, competitor_group_id, competitor_group_name, competitor_class, n_class_candidates, competitor_rank, competitor_score, n_collisions, n_colliding_families, n_subject_families, n_same_action, n_shared_indication_pairs, n_head_to_head_trials, top_collisions, n_cosponsored_trials].hash
|
|
410
318
|
end
|
|
411
319
|
|
|
412
320
|
# Builds the object from hash
|
|
@@ -61,6 +61,33 @@ module PharmaObservatory
|
|
|
61
61
|
# The latest fiscal year the filer reported any line item.
|
|
62
62
|
attr_accessor :latest_financial_fy
|
|
63
63
|
|
|
64
|
+
# The end of the latest reported quarter of the filer that has an operating cash flow figure (a 10-Q, or the Q4 derived from a 10-K); the date of the cash figure below. Repeated on every year row of the filer; null for a company with no quarterly SEC filings.
|
|
65
|
+
attr_accessor :quarter_end_date
|
|
66
|
+
|
|
67
|
+
# The date SEC received the filing of that latest quarter.
|
|
68
|
+
attr_accessor :quarter_filed_date
|
|
69
|
+
|
|
70
|
+
# Cash plus short-term investments at quarter_end_date, in USD (non-current investments are not counted).
|
|
71
|
+
attr_accessor :cash_and_investments_latest_q
|
|
72
|
+
|
|
73
|
+
# Net cash from operating activities of that latest quarter alone (year-to-date figures differenced; Q4 is the full year less nine months), in USD; negative means burning.
|
|
74
|
+
attr_accessor :operating_cash_flow_latest_q
|
|
75
|
+
|
|
76
|
+
# How many contiguous quarters burn_basis_quarterly_usd averages over, 1 or 2.
|
|
77
|
+
attr_accessor :burn_basis_quarters
|
|
78
|
+
|
|
79
|
+
# The mean quarterly operating cash flow over the latest two contiguous quarters (the latest alone when no contiguous earlier quarter has a figure), in USD; negative means burning.
|
|
80
|
+
attr_accessor :burn_basis_quarterly_usd
|
|
81
|
+
|
|
82
|
+
# An estimate, derived not reported: cash_and_investments_latest_q divided by the monthly burn (burn_basis_quarterly_usd over 3), in months at quarter_end_date, rounded to 0.1. Null whenever runway_quarterly_null_reason is set.
|
|
83
|
+
attr_accessor :runway_months_quarterly
|
|
84
|
+
|
|
85
|
+
# The version of the derivation behind runway_months_quarterly; trailing_quarter_mean_v1 is the mean of the latest two contiguous discrete quarters.
|
|
86
|
+
attr_accessor :runway_quarterly_method
|
|
87
|
+
|
|
88
|
+
# Why runway_months_quarterly is null, in precedence order: no_quarterly_facts (no 10-Q cash-flow facts: a private company or a 20-F/40-F filer), stale (the latest quarter ended over a year before the newest SEC filing loaded), no_fx_rate, no_cash_at_quarter_end, or positive_cash_flow (no burn to run out of). Null when the runway is published.
|
|
89
|
+
attr_accessor :runway_quarterly_null_reason
|
|
90
|
+
|
|
64
91
|
# Total revenue for the fiscal year, in USD (a non-USD filer is converted at the calendar-year average rate; null when no rate exists).
|
|
65
92
|
attr_accessor :revenue
|
|
66
93
|
|
|
@@ -172,6 +199,15 @@ module PharmaObservatory
|
|
|
172
199
|
:'latest_shares_outstanding' => :'latest_shares_outstanding',
|
|
173
200
|
:'latest_shares_outstanding_fy' => :'latest_shares_outstanding_fy',
|
|
174
201
|
:'latest_financial_fy' => :'latest_financial_fy',
|
|
202
|
+
:'quarter_end_date' => :'quarter_end_date',
|
|
203
|
+
:'quarter_filed_date' => :'quarter_filed_date',
|
|
204
|
+
:'cash_and_investments_latest_q' => :'cash_and_investments_latest_q',
|
|
205
|
+
:'operating_cash_flow_latest_q' => :'operating_cash_flow_latest_q',
|
|
206
|
+
:'burn_basis_quarters' => :'burn_basis_quarters',
|
|
207
|
+
:'burn_basis_quarterly_usd' => :'burn_basis_quarterly_usd',
|
|
208
|
+
:'runway_months_quarterly' => :'runway_months_quarterly',
|
|
209
|
+
:'runway_quarterly_method' => :'runway_quarterly_method',
|
|
210
|
+
:'runway_quarterly_null_reason' => :'runway_quarterly_null_reason',
|
|
175
211
|
:'revenue' => :'revenue',
|
|
176
212
|
:'net_income' => :'net_income',
|
|
177
213
|
:'rnd' => :'rnd',
|
|
@@ -234,6 +270,15 @@ module PharmaObservatory
|
|
|
234
270
|
:'latest_shares_outstanding' => :'Float',
|
|
235
271
|
:'latest_shares_outstanding_fy' => :'Integer',
|
|
236
272
|
:'latest_financial_fy' => :'Integer',
|
|
273
|
+
:'quarter_end_date' => :'Date',
|
|
274
|
+
:'quarter_filed_date' => :'Date',
|
|
275
|
+
:'cash_and_investments_latest_q' => :'Float',
|
|
276
|
+
:'operating_cash_flow_latest_q' => :'Float',
|
|
277
|
+
:'burn_basis_quarters' => :'Integer',
|
|
278
|
+
:'burn_basis_quarterly_usd' => :'Float',
|
|
279
|
+
:'runway_months_quarterly' => :'Float',
|
|
280
|
+
:'runway_quarterly_method' => :'String',
|
|
281
|
+
:'runway_quarterly_null_reason' => :'String',
|
|
237
282
|
:'revenue' => :'Float',
|
|
238
283
|
:'net_income' => :'Float',
|
|
239
284
|
:'rnd' => :'Float',
|
|
@@ -286,6 +331,15 @@ module PharmaObservatory
|
|
|
286
331
|
:'latest_shares_outstanding',
|
|
287
332
|
:'latest_shares_outstanding_fy',
|
|
288
333
|
:'latest_financial_fy',
|
|
334
|
+
:'quarter_end_date',
|
|
335
|
+
:'quarter_filed_date',
|
|
336
|
+
:'cash_and_investments_latest_q',
|
|
337
|
+
:'operating_cash_flow_latest_q',
|
|
338
|
+
:'burn_basis_quarters',
|
|
339
|
+
:'burn_basis_quarterly_usd',
|
|
340
|
+
:'runway_months_quarterly',
|
|
341
|
+
:'runway_quarterly_method',
|
|
342
|
+
:'runway_quarterly_null_reason',
|
|
289
343
|
:'revenue',
|
|
290
344
|
:'net_income',
|
|
291
345
|
:'rnd',
|
|
@@ -396,6 +450,42 @@ module PharmaObservatory
|
|
|
396
450
|
self.latest_financial_fy = attributes[:'latest_financial_fy']
|
|
397
451
|
end
|
|
398
452
|
|
|
453
|
+
if attributes.key?(:'quarter_end_date')
|
|
454
|
+
self.quarter_end_date = attributes[:'quarter_end_date']
|
|
455
|
+
end
|
|
456
|
+
|
|
457
|
+
if attributes.key?(:'quarter_filed_date')
|
|
458
|
+
self.quarter_filed_date = attributes[:'quarter_filed_date']
|
|
459
|
+
end
|
|
460
|
+
|
|
461
|
+
if attributes.key?(:'cash_and_investments_latest_q')
|
|
462
|
+
self.cash_and_investments_latest_q = attributes[:'cash_and_investments_latest_q']
|
|
463
|
+
end
|
|
464
|
+
|
|
465
|
+
if attributes.key?(:'operating_cash_flow_latest_q')
|
|
466
|
+
self.operating_cash_flow_latest_q = attributes[:'operating_cash_flow_latest_q']
|
|
467
|
+
end
|
|
468
|
+
|
|
469
|
+
if attributes.key?(:'burn_basis_quarters')
|
|
470
|
+
self.burn_basis_quarters = attributes[:'burn_basis_quarters']
|
|
471
|
+
end
|
|
472
|
+
|
|
473
|
+
if attributes.key?(:'burn_basis_quarterly_usd')
|
|
474
|
+
self.burn_basis_quarterly_usd = attributes[:'burn_basis_quarterly_usd']
|
|
475
|
+
end
|
|
476
|
+
|
|
477
|
+
if attributes.key?(:'runway_months_quarterly')
|
|
478
|
+
self.runway_months_quarterly = attributes[:'runway_months_quarterly']
|
|
479
|
+
end
|
|
480
|
+
|
|
481
|
+
if attributes.key?(:'runway_quarterly_method')
|
|
482
|
+
self.runway_quarterly_method = attributes[:'runway_quarterly_method']
|
|
483
|
+
end
|
|
484
|
+
|
|
485
|
+
if attributes.key?(:'runway_quarterly_null_reason')
|
|
486
|
+
self.runway_quarterly_null_reason = attributes[:'runway_quarterly_null_reason']
|
|
487
|
+
end
|
|
488
|
+
|
|
399
489
|
if attributes.key?(:'revenue')
|
|
400
490
|
self.revenue = attributes[:'revenue']
|
|
401
491
|
end
|
|
@@ -556,6 +646,15 @@ module PharmaObservatory
|
|
|
556
646
|
latest_shares_outstanding == o.latest_shares_outstanding &&
|
|
557
647
|
latest_shares_outstanding_fy == o.latest_shares_outstanding_fy &&
|
|
558
648
|
latest_financial_fy == o.latest_financial_fy &&
|
|
649
|
+
quarter_end_date == o.quarter_end_date &&
|
|
650
|
+
quarter_filed_date == o.quarter_filed_date &&
|
|
651
|
+
cash_and_investments_latest_q == o.cash_and_investments_latest_q &&
|
|
652
|
+
operating_cash_flow_latest_q == o.operating_cash_flow_latest_q &&
|
|
653
|
+
burn_basis_quarters == o.burn_basis_quarters &&
|
|
654
|
+
burn_basis_quarterly_usd == o.burn_basis_quarterly_usd &&
|
|
655
|
+
runway_months_quarterly == o.runway_months_quarterly &&
|
|
656
|
+
runway_quarterly_method == o.runway_quarterly_method &&
|
|
657
|
+
runway_quarterly_null_reason == o.runway_quarterly_null_reason &&
|
|
559
658
|
revenue == o.revenue &&
|
|
560
659
|
net_income == o.net_income &&
|
|
561
660
|
rnd == o.rnd &&
|
|
@@ -598,7 +697,7 @@ module PharmaObservatory
|
|
|
598
697
|
# Calculates hash code according to all attributes.
|
|
599
698
|
# @return [Integer] Hash code
|
|
600
699
|
def hash
|
|
601
|
-
[company_id, company_name, group_id, group_name, reporting_org_id, fiscal_year, is_public, edgar_cik, ticker, exchange, public_float_usd, public_float_fy, latest_shares_outstanding, latest_shares_outstanding_fy, latest_financial_fy, revenue, net_income, rnd, assets, equity, public_float, cash, short_term_investments, cash_and_investments, operating_cash_flow, shares_outstanding, stock_based_compensation, operating_expenses, dividends_paid, eps_basic, eps_diluted, total_liabilities, long_term_debt_noncurrent, long_term_debt_total, intangible_assets, property_plant_equipment, goodwill, inventory, accounts_payable, accounts_receivable, weighted_average_shares_basic, weighted_average_shares_diluted, burn_basis_usd, burn_basis_years, runway_months, sec_total_revenue_usd_millions].hash
|
|
700
|
+
[company_id, company_name, group_id, group_name, reporting_org_id, fiscal_year, is_public, edgar_cik, ticker, exchange, public_float_usd, public_float_fy, latest_shares_outstanding, latest_shares_outstanding_fy, latest_financial_fy, quarter_end_date, quarter_filed_date, cash_and_investments_latest_q, operating_cash_flow_latest_q, burn_basis_quarters, burn_basis_quarterly_usd, runway_months_quarterly, runway_quarterly_method, runway_quarterly_null_reason, revenue, net_income, rnd, assets, equity, public_float, cash, short_term_investments, cash_and_investments, operating_cash_flow, shares_outstanding, stock_based_compensation, operating_expenses, dividends_paid, eps_basic, eps_diluted, total_liabilities, long_term_debt_noncurrent, long_term_debt_total, intangible_assets, property_plant_equipment, goodwill, inventory, accounts_payable, accounts_receivable, weighted_average_shares_basic, weighted_average_shares_diluted, burn_basis_usd, burn_basis_years, runway_months, sec_total_revenue_usd_millions].hash
|
|
602
701
|
end
|
|
603
702
|
|
|
604
703
|
# Builds the object from hash
|
|
@@ -28,13 +28,21 @@ module PharmaObservatory
|
|
|
28
28
|
# Trials for this condition that report the term.
|
|
29
29
|
attr_accessor :n_trials
|
|
30
30
|
|
|
31
|
+
# Distinct serious adverse event terms across the condition's trials. The rows are only the top 10 of these, so a row count is not the term count; use this.
|
|
32
|
+
attr_accessor :n_terms_total
|
|
33
|
+
|
|
34
|
+
# Results-posting trials of the condition that report at least one serious adverse event term.
|
|
35
|
+
attr_accessor :n_trials_total
|
|
36
|
+
|
|
31
37
|
# Attribute mapping from ruby-style variable name to JSON key.
|
|
32
38
|
def self.attribute_map
|
|
33
39
|
{
|
|
34
40
|
:'condition_id' => :'condition_id',
|
|
35
41
|
:'adverse_event_term' => :'adverse_event_term',
|
|
36
42
|
:'subjects_affected' => :'subjects_affected',
|
|
37
|
-
:'n_trials' => :'n_trials'
|
|
43
|
+
:'n_trials' => :'n_trials',
|
|
44
|
+
:'n_terms_total' => :'n_terms_total',
|
|
45
|
+
:'n_trials_total' => :'n_trials_total'
|
|
38
46
|
}
|
|
39
47
|
end
|
|
40
48
|
|
|
@@ -54,7 +62,9 @@ module PharmaObservatory
|
|
|
54
62
|
:'condition_id' => :'String',
|
|
55
63
|
:'adverse_event_term' => :'String',
|
|
56
64
|
:'subjects_affected' => :'Float',
|
|
57
|
-
:'n_trials' => :'Integer'
|
|
65
|
+
:'n_trials' => :'Integer',
|
|
66
|
+
:'n_terms_total' => :'Integer',
|
|
67
|
+
:'n_trials_total' => :'Integer'
|
|
58
68
|
}
|
|
59
69
|
end
|
|
60
70
|
|
|
@@ -64,7 +74,9 @@ module PharmaObservatory
|
|
|
64
74
|
:'condition_id',
|
|
65
75
|
:'adverse_event_term',
|
|
66
76
|
:'subjects_affected',
|
|
67
|
-
:'n_trials'
|
|
77
|
+
:'n_trials',
|
|
78
|
+
:'n_terms_total',
|
|
79
|
+
:'n_trials_total'
|
|
68
80
|
])
|
|
69
81
|
end
|
|
70
82
|
|
|
@@ -99,6 +111,14 @@ module PharmaObservatory
|
|
|
99
111
|
if attributes.key?(:'n_trials')
|
|
100
112
|
self.n_trials = attributes[:'n_trials']
|
|
101
113
|
end
|
|
114
|
+
|
|
115
|
+
if attributes.key?(:'n_terms_total')
|
|
116
|
+
self.n_terms_total = attributes[:'n_terms_total']
|
|
117
|
+
end
|
|
118
|
+
|
|
119
|
+
if attributes.key?(:'n_trials_total')
|
|
120
|
+
self.n_trials_total = attributes[:'n_trials_total']
|
|
121
|
+
end
|
|
102
122
|
end
|
|
103
123
|
|
|
104
124
|
# Show invalid properties with the reasons. Usually used together with valid?
|
|
@@ -124,7 +144,9 @@ module PharmaObservatory
|
|
|
124
144
|
condition_id == o.condition_id &&
|
|
125
145
|
adverse_event_term == o.adverse_event_term &&
|
|
126
146
|
subjects_affected == o.subjects_affected &&
|
|
127
|
-
n_trials == o.n_trials
|
|
147
|
+
n_trials == o.n_trials &&
|
|
148
|
+
n_terms_total == o.n_terms_total &&
|
|
149
|
+
n_trials_total == o.n_trials_total
|
|
128
150
|
end
|
|
129
151
|
|
|
130
152
|
# @see the `==` method
|
|
@@ -136,7 +158,7 @@ module PharmaObservatory
|
|
|
136
158
|
# Calculates hash code according to all attributes.
|
|
137
159
|
# @return [Integer] Hash code
|
|
138
160
|
def hash
|
|
139
|
-
[condition_id, adverse_event_term, subjects_affected, n_trials].hash
|
|
161
|
+
[condition_id, adverse_event_term, subjects_affected, n_trials, n_terms_total, n_trials_total].hash
|
|
140
162
|
end
|
|
141
163
|
|
|
142
164
|
# Builds the object from hash
|